Neil Bryan Gamilla, MD
Family Medicine · Richmond, INNPI 1952564379
Payments from drug & device makers
Across 357 payments — averaging $13.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$458
- GSK$405
- Pfizer$312
- AstraZeneca$257
- Amgen$232
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,82998%
- Education$711%
- Other$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 138 | $1,296 |
| Novo Nordisk | 28 | $458 |
| GSK | 29 | $405 |
| Pfizer | 20 | $312 |
| AstraZeneca | 14 | $257 |
| Amgen | 14 | $232 |
| Lilly USA, LLC | 15 | $231 |
| Vanda Pharmaceuticals Inc. | 17 | $215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $202 |
| Otsuka America Pharmaceutical, Inc. | 8 | $161 |
| Boehringer Ingelheim | 9 | $150 |
| Abbott | 6 | $134 |
| Coopersurgical, Inc. | 3 | $115 |
| Lundbeck LLC | 6 | $108 |
| Bayer | 4 | $75 |
| Phathom Pharmaceuticals, Inc. | 6 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Exact Sciences | 4 | $70 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Corium, LLC | 3 | $45 |
| Ironshore Pharmaceuticals Inc. | 2 | $36 |
| Novartis | 2 | $36 |
| Alkermes, Inc. | 2 | $33 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Tris Pharma Inc | 1 | $17 |
| Merck | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$4,950 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $154,984 |
| EliquisApixaban | 115 | $90,711 |
| JardianceEmpagliflozin | 75 | $79,322 |
| VraylarCariprazine Hcl | 43 | $61,666 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $55,724 |
| MounjaroTirzepatide | 39 | $41,781 |
| RexultiBrexpiprazole | 40 | $40,328 |
| TrulicityDulaglutide | 32 | $34,801 |
| XareltoRivaroxaban | 18 | $23,023 |
| FarxigaDapagliflozin Propanediol | 20 | $18,325 |
| LinzessLinaclotide | 31 | $16,584 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $16,394 |
| TradjentaLinagliptin | 18 | $12,222 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $10,445 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $10,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $458 | $154,984111 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $150 | $98,950109 claims |
| PfizerEliquis, Paxlovid | $312 | $94,851129 claims |
| AbbVieVraylar, Linzess | $1,296 | $78,25174 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $405 | $78,076123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $231 | $76,58271 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $161 | $40,32840 claims |
| Johnson & JohnsonXarelto | $18 | $23,02318 claims |
| AstraZenecaFarxiga | $257 | $18,32520 claims |
| MerckBelsomra | $17 | $6,97914 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $72 | $5,59716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Richmond
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.